FDA finalized three guidances telling cancer trial sponsors to justify lab value, performance status, and washout period exclusions rather than copying them.
FDA Tells Cancer Trial Sponsors to Stop Copying Eligibility Rules That Lack Scientific Support
by | Aug 4, 2026 | Uncategorized | 0 comments
Recent Comments